The promise and perils of HDAC inhibitors in neurodegeneration.

The promise and perils of HDAC inhibitors in neurodegeneration.
复制标题

DOI:
10.1002/acn3.147
复制
发表时间:
2015-01
影响因子:
5.3
通讯作者:
Opal, Puneet
Opal, Puneet
中科院分区:
医学2区
文献类型:
--
作者:
Didonna, Alessandro;Opal, Puneet

文献摘要

参考文献

被引文献

相似文献

组蛋白去乙酰化酶(HDAC)代表神经变性背景下的新兴治疗靶标。事实上,神经系统中HDAC活性的药理学抑制已在几种神经系统疾病的临床前模型中显示出有益的效果。然而,这种治疗方法在临床上的应用仅取得了轻微的成功,这主要是由于我们对HDAC的生理作用,特别是在神经元中的生理作用的了解仍然有限。在这里,我们回顾了潜在的好处沿着的风险,根据我们目前所知道的HDAC在大脑中的活动。
Histone deacetylases (HDACs) represent emerging therapeutic targets in the context of neurodegeneration. Indeed, pharmacologic inhibition of HDACs activity in the nervous system has shown beneficial effects in several preclinical models of neurological disorders. However, the translation of such therapeutic approach to clinics has been only marginally successful, mainly due to our still limited knowledge about HDACs physiological role particularly in neurons. Here, we review the potential benefits along with the risks of targeting HDACs in light of what we currently know about HDAC activity in the brain.
DOI: 10.1093/hmg/8.9.1647
发表时间: 1999-09-01
影响因子: 3.5
作者:
Boutell, JM;Thomas, P;Jones, AL
通讯作者: Jones, AL
DOI: 10.1038/ncomms3532
发表时间: 2013
影响因子: 16.6
作者:
Ageta-Ishihara, Natsumi;Miyata, Takaki;Ohshima, Chika;Watanabe, Masahiko;Sato, Yoshikatsu;Hamamura, Yuki;Higashiyama, Tetsuya;Mazitschek, Ralph;Bito, Haruhiko;Kinoshita, Makoto
通讯作者: Kinoshita, Makoto
DOI: 10.1371/journal.pone.0034805
发表时间: 2012
期刊: PloS one
影响因子: 3.7
作者:
Bobrowska A;Donmez G;Weiss A;Guarente L;Bates G
通讯作者: Bates G
DOI: 10.1172/jci29562
发表时间: 2007-03-01
影响因子: 15.9
作者:
Avila, Amy M.;Burnett, Barrington G.;Sumner, Charlotte J.
通讯作者: Sumner, Charlotte J.
DOI: 10.1073/pnas.261574398
发表时间: 2001-12-18
影响因子: 11.1
作者:
Bedalov, A;Gatbonton, T;Simon, JA
通讯作者: Simon, JA